The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Abstract
Gendicine (recombinant human p53 adenovirus), developed by Shenzhen SiBiono GeneTech Co. Ltd., was approved in 2003 by the China Food and Drug Administration (CFDA) as a first-in-class gene therapy product to treat head and neck cancer, and entered the commercial market in 2004. Gendicine is a biological therapy that is delivered via minimally invasive intratumoral injection, as well as by intracavity or intravascular infusion. The wild-type (wt) p53 protein expressed by Gendicine-transduced cells is a tumor suppressor that is activated by cellular stress, and mediates cell-cycle arrest and DNA repair, or induces apoptosis, senescence, and/or autophagy, depending upon cellular stress conditions. Based on 12 years of commercial use in >30,000 patients, and >30 published clinical studies, Gendicine has exhibited an exemplary safety record, and when combined with chemotherapy and radiotherapy has demonstrated significantly higher response rates than for standard therapies alone. In addition to head and neck cancer, Gendicine has been successfully applied to treat various other cancer types and different stages of disease. Thirteen published studies that include long-term survival data showed that Gendicine combination regimens yield progression-free survival times that are significantly longer than standard therapies alone. Although the p53 gene is mutated in >50% of all human cancers, p53 mutation status did not significantly influence efficacy outcomes and long-term survival rate for Ad- p53 -treated patients. To date, Shenzhen SiBiono GeneTech has manufactured 41 batches of Gendicine in compliance with CFDA QC/QA requirements, and 169,571 vials (1.0 × 10 12 vector particles per vial) have been used to treat patients. No serious adverse events have been reported, except for vector-associated transient fever, which occurred in 50–60% of patients and persisted for only a few hours. The manufacturing accomplishments and clinical experience with Gendicine, as well as the understanding of its cellular mechanisms of action and implications, could provide valuable insights for the international gene therapy community and add valuable data to promote further developments and advancements in the gene therapy field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gendicine, the first p53 gene therapy, is a recombinant human p53 adenovirus that was approved in 2003 by the China Food and Drug Administration (CFDA) for the treatment of HNSCC.399”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [399]
In the citing paper
“Many clinical studies have demonstrated that gendicine is safe and has better efficacy when combined with radiotherapy or chemotherapy than does gendicine alone.399”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [399]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Tu, K., Zheng, X. M., Zhou, Z., Li, C., Zhang, J., Gao, J., Yao, Y., & Liu, Q. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068574 · Cited by 58
Retractedp53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma
Guan, Y., Liu, Y., Zhou, X. P., Li, X., He, Q., & Sun, L. (2005) · Gut · doi:10.1136/gut.2005.069237 · Cited by 28
Self-citationRetractedCharacteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
p53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · cited 1×
“In 137–139”
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis
Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., Gasco, M., Garrone, O., Crook, T., & Ryan, K. M. (2006) · Cell · doi:10.1016/j.cell.2006.05.034 · Cited by 1,380
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Haupt, S., Berger, M., Goldberg, Z., & Haupt, Y. (2003) · Journal of Cell Science · doi:10.1242/jcs.00739 · Cited by 1,136
Bolós, V., Peinado, H., Pérez-Moreno, M. A., Fraga, M. F., Esteller, M., & Cano, A. (2003) · Journal of Cell Science · doi:10.1242/jcs.00224 · Cited by 1,100
Welcker, M., & Clurman, B. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2290 · Cited by 1,084
p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload
Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., Akazawa, H., Tateno, K., Kayama, Y., Harada, M., et al. (2007) · Nature · doi:10.1038/nature05602 · Cited by 905
p53 and E2F-1 cooperate to mediate apoptosis.
Wu, X., & Levine, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3602 · Cited by 839
Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730
The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression
Schwartzenberg-Bar-Yoseph, F., Armoni, M., & Karnieli, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0846 · Cited by 726
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Self-citationMcGrory, W. J., Bautista, D. S., & Graham, F. L. (1988) · Virology · doi:10.1016/0042-6822(88)90302-9 · Cited by 593
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Ordered Cooperative Functions of PRMT1, p300, and CARM1 in Transcriptional Activation by p53
An, W., Kim, J., & Roeder, R. G. (2004) · Cell · doi:10.1016/j.cell.2004.05.009 · Cited by 511
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 481
Overexpression and mutation of p53 in epithelial ovarian cancer.
Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke‐Pearson, D. L., Iglehart, J. D., Bast, R. C., & Berchuck, A. (1991) · PubMed · Cited by 464
p53 and its mutants in tumor cell migration and invasion
Muller, P. A. J., Vousden, K. H., & Norman, J. C. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009059 · Cited by 463
Metabolic Regulation by p53 Family Members
Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I., & Vousden, K. H. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.019 · Cited by 446
Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Peng, Z. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1016 · Cited by 436
Ganly, I., Kirn, D. H., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C. C., et al. (2000) · PubMed · Cited by 432
Brady, C. A., & Attardi, L. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.064501 · Cited by 403
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 395
Wu, H., & Lozano, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32128-2 · Cited by 361
A dual role of p53 in the control of autophagy
Tasdemir, E., Maiuri, M. C., Morselli, E., Criollo, A., D'Amelio, M., Djavaheri-Mergny, M., Cecconi, F., Tavernarakis, N., & Kroemer, G. (2008) · Autophagy · doi:10.4161/auto.6486 · Cited by 345
Zhou, G., Liu, Z., & Myers, J. N. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25592 · Cited by 343
The p53 tumor suppressor participates in multiple cell cycle checkpoints
Giono, L. E., & Manfredi, J. J. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20689 · Cited by 328
White, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026120 · Cited by 320
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308
Jin, S., & Levine, A. J. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.23.4139 · Cited by 307
Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C., & Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301398 · Cited by 299
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
Teodoro, J. G., Evans, S. K., & Green, M. R. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0221-2 · Cited by 260
Zhang, W. W., Fang, X., Mazur, W. M., French, B. A., Georges, R. N., & Roth, J. A. (1994) · PubMed · Cited by 257
Self-citationMdm2 association with p53 targets its ubiquitination
Fuchs, S. Y., Adler, V., Buschmann, T., Wu, X., & Ronai, Z. (1998) · Oncogene · doi:10.1038/sj.onc.1202200 · Cited by 236
Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M.-T., Huang, W.-M., Johnson, D. E., Anderson, S. C., Wen, S. F., et al. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.9-1079 · Cited by 233
Zhang, L., Yu, D., Hu, M., Xiong, S., Lang, A., Ellis, L. M., & Pollock, R. E. (2000) · PubMed · Cited by 229
Deconstructing networks of p53-mediated tumor suppression in vivo
Kaiser, A. M., & Attardi, L. D. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.171 · Cited by 227
Zhang, P., Tu, B., Wang, H., Cao, Z., Tang, M., Zhang, C., Gu, B., Li, Z., Wang, L., Yang, Y., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411026111 · Cited by 224
Shih, J.-Y., Tsai, M.-F., Chang, T.-H., Chang, Y.-L., Yuan, A., Yu, C.-J., Lin, S.-B., Liou, G.-Y., Lee, M.-L., Chen, J. J. W., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0687 · Cited by 210
The cell fate: senescence or quiescence
Terzi, M. Y., Izmirli, M., & Gogebakan, B. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4065-0 · Cited by 208
DRAM Links Autophagy to p53 and Programmed Cell Death
Crighton, D., Wilkinson, S., & Ryan, K. M. (2007) · Autophagy · doi:10.4161/auto.3438 · Cited by 202
p53 transformation-related protein: Detection by monoclonal antibody in mouse and human cells
Dippold, W. G., Jay, G., DeLeo, A. B., Khoury, G., & Old, L. J. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.3.1695 · Cited by 201
Why did p53 gene therapy fail in ovarian cancer?
Zeimet, A. G., & Marth, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01139-2 · Cited by 199
Lowe, S. W. (1995) · Current Opinion in ONCOLOGY · doi:10.1097/00001622-199511000-00013 · Cited by 194
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 194
Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185
A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer
Mello, S. S., Valente, L. J., Raj, N., Seoane, J. A., Flowers, B. M., McClendon, J., Bieging-Rolett, K. T., Lee, J., Ivanochko, D., Kozak, M. M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.007 · Cited by 179
FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug
Bach, P. B., Giralt, S. A., & Saltz, L. B. (2017) · JAMA · doi:10.1001/jama.2017.15218 · Cited by 167
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
Buller, R. E., Runnebaum, I. B., Karlan, B. Y., Horowitz, J. A., Shahin, M., Buekers, T., Petrauskas, S., Kreienberg, R., Slamon, D., & Pegram, M. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700472 · Cited by 164
Haq, R., Brenton, J. D., Takahashi, M. T., Finan, D., Finkielsztein, A., Damaraju, S., Rottapel, R. K., & Zanke, B. W. (2002) · PubMed · Cited by 143
A core viral protein binds host nucleosomes to sequester immune danger signals
Avgousti, D. C., Herrmann, C., Kulej, K., Pancholi, N. J., Sekulić, N., Petrescu, J., Molden, R. C., Blumenthal, D., Paris, A. J., Reyes, E. D., et al. (2016) · Nature · doi:10.1038/nature18317 · Cited by 140
Cui, Y. R., & Guo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111942 · Cited by 140
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
Roberts, Z. J., Better, M., Bot, A. I., Roberts, M. R., & Ribas, A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1387905 · Cited by 139
Targeting p53 for enhanced radio- and chemo-sensitivity
Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 138
Harrington, K. J., Puzanov, I. J., Hecht, J. R., Hodi, F. S., Szabó, Z. R., Murugappan, S., & Kaufman, H. L. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1115725 · Cited by 134
Gendicine: The First Commercial Gene Therapy Product; Chinese Translation of Editorial
Wilson, J. M. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1014 · Cited by 130
Twist and p53 reciprocally regulate target genes via direct interaction
Shiota, M., Izumi, H., Onitsuka, T., Miyamoto, N., Kashiwagi, E., Kidani, A., Hirano, G., Takahashi, M., Naito, S., & Kohno, K. (2008) · Oncogene · doi:10.1038/onc.2008.176 · Cited by 128
Nielsen, L. L., Lipari, P., Dell, J., Gurnani, M., & Hajian, G. (1998) · PubMed · Cited by 125
Death but one unintended consequence of gene-therapy trial.
Sibbald, B. (2001) · PubMed · Cited by 124
Pan, J.-J., Zhang, S., Chen, C.-B., Xiao, S., Sun, Y. P., Liu, C., Su, X., Li, D., Xu, G., Xu, B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9670 · Cited by 124
Self-citationSafety Evaluation of Ad5CMY- p53 In Vitro and In Vivo
Zhang, W., Alemany, R., Wang, J., Koch, P. E., Ordóǹez, N. G., & Roth, J. A. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.2-155 · Cited by 119
Self-citationNishizaki, M., Fujiwara, T., Tanida, T., HIZUTA, A., Nishimori, H., Tokino, T., Nakamura, Y., Bouvet, M., Roth, J., & Tanaka, N. (1999) · PubMed · doi:10.11501/3168375 · Cited by 118
Gene therapy for cancer: regulatory considerations for approval
Husain, S., Han, J., Au, P., Shannon, K., & Puri, R. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.58 · Cited by 112
Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based Constructs
Alonso-Padilla, J., Papp, T., Kaján, G. L., Benkő, M., Havenga, M. J. E., Lemckert, A. A. C., Harrach, B., & Baker, A. H. (2015) · Molecular Therapy · doi:10.1038/mt.2015.194 · Cited by 105
p53-mediated autophagic regulation: A prospective strategy for cancer therapy
Tang, J., Di, J., Cao, H., Bai, J., & Zheng, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.014 · Cited by 105
Nemunaitis, J. J., Clayman, G. L., Agarwala, S. S., Hrushesky, W. J. M., Wells, J. R., Moore, C. E., Hamm, J. T., Yoo, G. H., Baselga, J. M., Murphy, B. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1044 · Cited by 91
Endo, Y., Sakai, R., Ouchi, M., Onimatsu, H., Hioki, M., Kagawa, S., Uno, F., Watanabe, Y., Urata, Y., Tanaka, N., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210884 · Cited by 87
Yang, Z., Wang, D., Wang, G., Zhang, Q.-H., Liu, J.-M., Peng, P., & Liu, X. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0701-6 · Cited by 87
Self-citationDeben, C., Deschoolmeester, V., Lardon, F., Rolfo, C. D., & Pauwels, P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.019 · Cited by 87
Dai, F., Chen, Y., Song, Y., Huang, L., Zhai, D., Dong, Y., Lai, L., Zhang, T., Li, D., Pang, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052162 · Cited by 77
Self-citationClinical utility of recombinant adenoviral human p53 gene therapy: current perspectives
Chen, G., Zhang, S. J., He, X., Liu, S., Ma, C., & Zou, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s50483 · Cited by 76
Advances in adenovirus-mediated p53 cancer gene therapy
Tazawa, H., Kagawa, S., & Fujiwara, T. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.845662 · Cited by 66
Yen, N., Ioannides, C. G., Xu, K., Swisher, S. G., Lawrence, D. D., Kemp, B. L., El‐Naggar, A. K., Cristiano, R. J., Fang, B., Glisson, B. S., et al. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700138 · Cited by 65
The interplay between epigenetic changes and the p53 protein in stem cellsPreprint
Levine, A. J., & Berger, S. L. (2017) · Genes & Development · doi:10.1101/gad.298984.117 · Cited by 63
Brasseur, G., Infossi, P., Dujardin, G., Słonimski, P. P., & Brivet‐Chevillotte, P. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-1-00103.x · Cited by 60
Tian, G., Liu, J., Zhou, J., & Chen, W. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832a2df9 · Cited by 56
Self-citationLei, H., Xu, Y., Chen, J., et al. (2010) · Virology · doi:10.1016/j.virol.2010.08.007 · Cited by 56
Wolf, J. K., Mills, G. B., Bazzet, L., Bast, R. C., Roth, J. A., & Gershenson, D. M. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5565 · Cited by 54
Cheng, G., Kong, D., Hou, X., Liang, B., He, M., Liang, N., Ma, S., & Liu, X. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1297 · Cited by 52
Olotu, F. A., & Soliman, M. E. S. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26430 · Cited by 51
Frank, D. K., Frederick, M. J., Liu, T. J., & Clayman, G. L. (1998) · PubMed · Cited by 50
Iiizumi, M., Arakawa, H., Mori, T., Ando, A., & Nakamura, Y. (2002) · PubMed · Cited by 49
Guo, G., & Cui, Y. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0053-5 · Cited by 49
p53 dynamics orchestrates with binding affinity to target genes for cell fate decision
Wu, M., Ye, H., Tang, Z., Shao, C., Lu, G., Chen, B., Yang, Y., Wang, G., & Hao, H. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.492 · Cited by 49
Kong, D., Ma, S., Liang, B., Yi, H., Zhao, Y., Xin, R., Cui, L., Jia, L., Liu, X., & Liu, X. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.12.002 · Cited by 43
Li, Y., Li, L., Zhang, S., Wang, L., Zhang, Z., Gao, N., Zhang, Y., & Chen, Q. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1296 · Cited by 43
Self-citationLi, Y., Li, B., Li, C., & Li, L. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.990882 · Cited by 41
Self-citationGuan, Y., Liu, Y., Zou, Q., He, Q., La, Z., Yang, L., & Hu, Y. C. (2009) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b0820248 · Cited by 38
Qiu, W., Wu, J., Walsh, E. M., Zhang, Y., Chen, C. Y., Fujita, J., & Xiao, Z.-X. J. (2008) · Oncogene · doi:10.1038/onc.2008.43 · Cited by 37
Noon, A. P., Polański, R., Elfert, A. Y., Kalirai, H., Shawki, H., Campbell, F., Dodson, A., Eccles, R. M., Lloyd, B. H., Sibson, D. R., et al. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10433.x · Cited by 34
Su, X., Chen, W., Xiao, S., Li, X., Xu, G., Pan, J.-J., & Zhang, S.-W. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.043 · Cited by 33
Self-citationEndostatin gene therapy for liver cancer by a recombinant adenovirus delivery
Li, L. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i13.1867 · Cited by 31
Self-citationDong, M., Li, X., Hong, L.-J., Xie, R., Zhao, H.-L., Li, K., Wang, H. H., Shin, W.-D., & Shen, H.-J. (2008) · Journal of International Medical Research · doi:10.1177/147323000803600614 · Cited by 28
Self-citationrAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy
Chen, G., Zheng, L.-H., Liu, S.-Y., & He, X.-H. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i38.4289 · Cited by 25
Advances in Cancer Gene Therapy
Zhang, W. W., Fujiwara, T., Grimm, E. A., & Roth, J. A. (1995) · Advances in pharmacology · doi:10.1016/s1054-3589(08)61016-9 · Cited by 24
Self-citationLebedeva, S., Bagdasarova, S., Tyler, T., Mu, X. Y., Wilson, D. R., & Gjerset, R. A. (2001) · Human Gene Therapy · doi:10.1089/104303401750148685 · Cited by 20
Saito, H., Kitagawa, K., Yoneda, T., Fukui, Y., Fujsawa, M., Bautista, D., & Shirakawa, T. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.21 · Cited by 19
Head and neck cancer: Gene therapy approaches. Part 1: Adenoviral vectors
Nemunaitis, J. J., & O’Brien, J. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.2.177 · Cited by 16
Biaoxue, R., Hui, P., Wenlong, G., & Shuanying, Y. (2016) · Scientific Reports · doi:10.1038/srep39355 · Cited by 16
Li, X., Xiao, S., Li, Y., et al. (2013) · PubMed · doi:10.3978/j.issn.1000-9604.2013.12.05 · Cited by 14
Self-citationAdenoviral vectors: development and application
Zhang, W.-W. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.10.1419 · Cited by 10
Self-citationThe First Twenty-Five Years of p53 Research
Robins, H. S., Alexe, G., Harris, S. L., & Levine, A. J. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_1 · Cited by 9
Hodorová, I., Rybárová, S., Vecanová, J., Solár, P., Plank, L., & Mihálik, J. (2012) · Acta Histochemica · doi:10.1016/j.acthis.2012.08.001 · Cited by 9
Ma, J., Han, C., Zhao, J., Jing, W., Zhou, Y., Huang, L., & Zou, H. (2012) · Oncology Letters · doi:10.3892/ol.2012.747 · Cited by 8
Cited by
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Metadata
- Authors
- Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., Hu, A., Xu, W., & Lam, D. M.-K.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2018-02
- Volume
- 29
- Issue
- 2
- Pages
- 160-179
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2784338572
- Cited by
- 318
- References
- 112
- FWCI
- 17.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.